EFTA Document EFTA01915748

To: From: on behalf of Sana Alajmovic < Sent: Tue 12/4/2012 10:38:16 PM Subject: Re: Mr. G. Steven Burrill Ha - it's a long life! Besides, I'm a handful.... But, would you approve of a brief introduction to Mr. Burrill? By the way, check this out: http://www.mynewsdesk.com/se/pressrootninanolggica/pressrelcaseiview/sana-alajmovic- avpointed-head-of-business-development-at-natmlogica-817705' Greetings from NanoSana:) On Tuc, Dec 4, 2012 at 11:34 PM, Jeffrey Epstein a > wrote: sorry i didn't get to meet you , that was the main dissappointment On Tuc, Dec 4, 2012 at 11:14 PM, Sana Alajmovic < wrote: Dear Jeffrey, We are sad that you could not join us last Saturday but I understand you have a busy schedule. I wanted to ask you whether I have your permission to introduce you to Mr. G. Steven Burrill, Founder & CEO of Burrill & Company - a global venture capital firm within Life Sciences? I met him through SALSS and having on several occassions told him about the Jeffrey Epstein Foundation, he became very interested in your support of cutting edge research. Mr. Burrill himself was recognized as a biotech investment visionary by the Scientific American magazine (The Scientific American 50) in 2002. Please see below for full bio. I am confident that the two of you would have a great intellectual exchange. Kindest, Sana G. Steven Burrill Chief Executive Officer > EFTA_R1_00355060 EFTA01915748 G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer of Burrill & Company, a venture capital and merchant banking firm, since 1994. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (NASDAQ: NVDQ), Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of Biolmagene, Abunda Nutrition and Pharmasset. Mr. Burrill is a founder and currently serves as Chairman of the Board of the National Science and Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. His other non-profit activities include serving as Chairman of the Boards of Directors of the Life Science Foundation, the World Council for Ethical Standards, the Vilas County (Wisconsin) Economic Development Corporation (VCEDC) and as Vice Chairman of the National Health Museum. He is also on the Boards of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), the Buck Institute for Research on Aging, the California Healthcare Institute (Emeritus), The Exploratorium (Emeritus), the Gladstone Foundation, the Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, BIO Ventures for Global Health (BVGH), the Harvard Medical School Genetics Advisory Council and the NIH Scientific Management Review Board. In 2012 Mr. Burrill received the Richard Bolte, Sr. Award for Supporting Industries from the Chemical Heritage Foundation in Philadelphia for his biotechnology industry leadership worldwide. In 2011 he received a lifetime achievement award at Scrip Intelligence's annual Scrip Award ceremony in London. That same year he received the Breath of Life Award from the Northern California Chapter of the Cystic Fibrosis Foundation to honor his contributions to the life sciences industry. In 2008 he received both the BayBio Pantheon DiNA lifetime achievement award for his biotech leadership worldwide, and the Alan Cranston Living Legend Award for his central role in advancing biomedical research globally. In 2002 he was recognized as a biotech investment visionary by the Scientific American magazine (The Scientific American 50), and was also honored that year at the American Liver Foundation's Annual "Salute to Excellence" Gala, which honors the leaders from the Bay Area's medical, biotech and bio-pharmaceutical industries. In 1995 Mr. Burrill received BIO's "service award" for his global biotechnology leadership. He serves on the editorial boards of Scientific American, the Journal of Commercial Biotechnology and Life Science Leader and on the advisory boards of the Center for Policy on Emerging Technologies (C-PET) and BioAg Gateway, City of Madison. He is an advisor to the University of Illinois Institute for Genomic Biology, EFTA_R1_00355061 EFTA01915749 the University of Wisconsin-College of Agriculture and Life Sciences, the University of Minnesota College of Biological Sciences, University of California, Davis, and Duke University, and is an adjunct professor at University of California, San Francisco. He also serves on the Advisory Boards for the Department of Biology at San Francisco State University and the Biotechnology Master's Program in the Department of Biology at the University of San Francisco. He serves on the BioNJ Diagnostics and Personalized Medicine Committee. Mr. Burrill earned a BBA degree from the University of Wisconsin, Madison. Sana Alajmovic Director, Business Development 1u1' ******************************************A**************** The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail t , and destroy this communication an a copies t tereo , including all attachments. copyright -all rights reserved Sana Alajmovic Director, Business Development The Swedish-American Life Science Summit 2012 EFTA_R1_00355062 EFTA01915750 EFTA_R1_00355063 EFTA01915751